Administrative/Regulatory
May 4, 2012
Generic drugs and the new norm in pharmaceutical litigation
The impact of PLIVA is to let many generic manufacturers off the hook. By Patricia L. Zlaket of Case Cherry Schenk Francavilla Blatt & Penfield LLP
The U.S. Supreme Court decision in PLIVA, Inc., et al. v. Mensing, 131 S.Ct. 2567 (2011), gave more power to drug companies, while appearing to give plaintiffs little recourse for injury or death caused by a generic pharmaceutical product. The ruling has significant consequence for attorneys who practice pharmaceutical litigation - limiting the cases they can...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In